First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors - ScienceDirect
![](https://ars.els-cdn.com/content/image/1-s2.0-S2589537021000778-gr1.jpg)
![](https://ars.els-cdn.com/content/image/1-s2.0-S1550413122004478-fx1.jpg)
The role of lipids in cancer progression and metastasis
![](https://christie.openrepository.com/bitstream/handle/10541/624019/33870151.pdf.jpg?sequence=4&isAllowed=y)
First-in-human study of the safety, pharmacokinetics, and
![](https://ars.els-cdn.com/content/image/1-s2.0-S0753332223015391-gr5.jpg)
Acetyl-CoA metabolism as a therapeutic target for cancer
![](https://www.researchgate.net/profile/Jing-Xiong-15/publication/354886240/figure/tbl2/AS:1098754333655042@1638974855179/Agents-targeting-metabolism-for-the-treatment-of-HCC-in-clinical-trials-Compd-Highest_Q320.jpg)
PDF) Metabolic dysregulation and emerging therapeutical targets
![](https://i1.rgstatic.net/publication/350523868_First-in-human_study_of_the_safety_pharmacokinetics_and_pharmacodynamics_of_first-in-class_fatty_acid_synthase_inhibitor_TVB-2640_alone_and_with_a_taxane_in_advanced_tumors/links/607f08ff881fa114b4167998/largepreview.png)
PDF) First-in-human study of the safety, pharmacokinetics, and
![](https://www.frontiersin.org/files/myhome%20article%20library/496787/496787_Thumb_400.jpg)
Frontiers First-In-Human Study to Assess the Safety
![](https://www.researchgate.net/profile/Jing-Xiong-15/publication/354886240/figure/tbl1/AS:1098754333655041@1638974855165/continued_Q320.jpg)
PDF) Metabolic dysregulation and emerging therapeutical targets
![](https://cdn.agilitycms.com/applied-radiology/Images/Liver%20cancer.jpg)
FASCINATE Phase 2a Trial Evaluating TVB-2640 Shows Reduced Excess
![](https://ars.els-cdn.com/content/image/1-s2.0-S0753332223013896-ga1.jpg)
Targeting fatty acid uptake and metabolism in cancer cells: A
![](https://ars.els-cdn.com/content/image/1-s2.0-S0753332223015391-ga1.jpg)
Acetyl-CoA metabolism as a therapeutic target for cancer
![](https://www.natap.org/2021/images/112021/112021-2/1120212.gif)
Novel, first-in-class, fatty acid synthase inhibitor, TVB-2640
![](https://ars.els-cdn.com/content/image/1-s2.0-S2211383522000752-gr5.jpg)
Suppressing fatty acid synthase by type I interferon and chemical
![](https://ars.els-cdn.com/content/image/1-s2.0-S002222752200089X-gr6.jpg)
FASN inhibitor TVB-3166 prevents S-acylation of the spike protein
![](https://ars.els-cdn.com/content/image/1-s2.0-S0753332223013896-gr1.jpg)
Targeting fatty acid uptake and metabolism in cancer cells: A